Veru Inc. (NASDAQ:VERU – Get Rating) – Research analysts at Oppenheimer reduced their FY2024 EPS estimates for shares of Veru in a research note issued to investors on Thursday, May 12th. Oppenheimer analyst L. Gershell now anticipates that the company will earn $0.42 per share for the year, down from their previous estimate of $0.44. Oppenheimer has a “Outperform” rating and a $36.00 price objective on the stock. Oppenheimer also issued estimates for Veru’s FY2025 earnings at $2.24 EPS.
Veru (NASDAQ:VERU – Get Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.02). Veru had a negative net margin of 45.56% and a negative return on equity of 18.15%. During the same period in the previous year, the company posted ($0.04) earnings per share.
Other equities research analysts also recently issued research reports about the company. HC Wainwright boosted their price objective on Veru from $21.00 to $24.00 and gave the company a “buy” rating in a report on Tuesday, April 12th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Veru in a research report on Friday. Zacks Investment Research lowered Veru from a “buy” rating to a “hold” rating in a research report on Thursday, April 21st. Jefferies Financial Group increased their price target on Veru from $33.00 to $55.00 in a research report on Friday. Finally, TheStreet raised Veru from a “d+” rating to a “c” rating in a research report on Friday, April 29th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, Veru presently has an average rating of “Buy” and a consensus target price of $32.75.
VERU stock opened at $13.00 on Monday. The company has a market capitalization of $1.04 billion, a PE ratio of -38.23 and a beta of -0.57. Veru has a 12-month low of $4.34 and a 12-month high of $17.50. The business’s fifty day moving average price is $8.17 and its 200 day moving average price is $7.04.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Teacher Retirement System of Texas raised its position in shares of Veru by 22.4% during the 4th quarter. Teacher Retirement System of Texas now owns 12,360 shares of the company’s stock worth $73,000 after acquiring an additional 2,258 shares in the last quarter. XTX Topco Ltd raised its position in shares of Veru by 18.7% during the 1st quarter. XTX Topco Ltd now owns 14,426 shares of the company’s stock worth $70,000 after acquiring an additional 2,270 shares in the last quarter. Rhumbline Advisers raised its position in shares of Veru by 3.6% during the 1st quarter. Rhumbline Advisers now owns 68,654 shares of the company’s stock worth $332,000 after acquiring an additional 2,410 shares in the last quarter. Swiss National Bank raised its position in shares of Veru by 2.0% during the 3rd quarter. Swiss National Bank now owns 140,900 shares of the company’s stock worth $1,202,000 after acquiring an additional 2,700 shares in the last quarter. Finally, Ignite Planners LLC raised its position in shares of Veru by 7.0% during the 1st quarter. Ignite Planners LLC now owns 45,875 shares of the company’s stock worth $514,000 after acquiring an additional 3,000 shares in the last quarter. 29.11% of the stock is currently owned by institutional investors and hedge funds.
Veru Company Profile (Get Rating)
Veru Inc, an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N.
Receive News & Ratings for Veru Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Veru and related companies with MarketBeat.com’s FREE daily email newsletter.